What is the current market size and future outlook for the diabetic peripheral neuropathy market?
The diabetic peripheral neuropathy market size has grown strongly in recent years. It will grow from $3.51 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to the rising geriatric population, increasing prevalence of diabetes, rising healthcare expenditure, growing awareness about diabetic complications, and increasing healthcare infrastructure.
The diabetic peripheral neuropathy market size is expected to see strong growth in the next few years. It will grow to $5.43 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to an increase in sedentary lifestyles, increased government initiatives and funding, increasing prevalence of neuropathy risk factors, improved diagnostic accuracy, and growing support for early detection and prevention. Major trends in the forecast period include advancements in diagnostic technologies, technological advancements in treatment options, higher investment in research and development, development of minimally invasive procedures, and enhanced focus on collaborative research and development.
Get Your Free Sample of The Global Diabetic Peripheral Neuropathy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp
How has the diabetic peripheral neuropathy market evolved, and what factors have shaped its growth?
The increase in obesity-related health issues is expected to propel the growth of the diabetic peripheral neuropathy market going forward. Obesity is a medical condition characterized by excessive body fat accumulation that may impair health and increase the risk of various chronic diseases. The increase in obesity-related health issues is due to rising awareness, lifestyle changes, and a growing need for preventive and treatment solutions, leading to increased healthcare demand. Diabetic peripheral neuropathy is helpful for obesity management. It provides critical insights into nerve damage caused by obesity-related conditions, guiding targeted interventions to improve overall patient well-being and quality of life. For instance, in March 2024, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for global public health, in 2022, 43% of adults aged 18 and over were classified as overweight, while 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight. Among children and adolescents aged 5 to 19 years, over 390 million were overweight, including 160 million affected by obesity. Therefore, the increase in obesity-related health issues is driving growth in the diabetic peripheral neuropathy market.
What are the major segments of the diabetic peripheral neuropathy market?
The diabetic peripheral neuropathy market covered in this report is segmented –
1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy
2) By Treatment: Pain Management Drugs, Gene Therapies
3) By Therapy: Antidepressants, Anticonvulsants
4) By Patient Population: Adult Patients, Geriatric Patients
Subsegments:
1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy
2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy
Order your report now for swift delivery
Which companies dominate the diabetic peripheral neuropathy market?
Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.
How will evolving trends contribute to the growth of the diabetic peripheral neuropathy market?
Major companies operating in the diabetic peripheral neuropathy market are focusing on technological innovations, such as NaV1.8 pain signal inhibitors, to provide patients with advanced, non-opioid treatments that improve pain management and overall quality of life. A NaV1.8 pain signal inhibitor is a specialized drug that blocks the NaV1.8 sodium channel, a key mediator of pain signals in sensory neurons, to provide relief from acute and neuropathic pain without relying on opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, announced advancements in its suzetrigine pain program, including initiating a Phase 3 pivotal program for treating pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has shown promising results in earlier studies and recently received Food and Drug Administration (FDA), a US-based federal agency breakthrough therapy designation for diabetic Peripheral Neuropathy (DPN)pain management.
What are the key regional dynamics of the diabetic peripheral neuropathy market, and which region leads in market share?
North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Diabetic Peripheral Neuropathy Market Report 2025 Offer?
The diabetic peripheral neuropathy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Diabetic Peripheral Neuropathy (DPN) is a nerve disorder caused by prolonged high blood sugar levels in individuals with diabetes, leading to nerve damage primarily in the legs, feet, arms, and hands. This condition occurs due to long-term high blood sugar levels, which damage the nerves and blood vessels, impairing nerve function and blood flow to the affected areas.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21170
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
